Biotech Values

[gfp927z]

Thanks Dew / board. Looking at the Lucentis Phase 3 data, it looks like vision was maintained or improved in 95% of patients after 1 year, vrs 62% for patients not receiving the drug (using a once/month injection regimen). They have another trial using less frequent injections (monthly for the first 3 months, then one injection every 3 months), but it looks like the results aren't nearly as good.

While the prospect of getting stuck in the eye every month isn't too appealing, it certainly beats the alternative. Thanks for the input.